Cargando…
Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience
BACKGROUND: Despite the advent of 5-HT(3) antagonists, control of delayed gastrointestinal adverse events with cancer chemotherapy is still not optimal. This open label, active controlled, multicentric clinical trial was undertaken to assess the comparative efficacy and safety of ramosetron with ond...
Autores principales: | Sanmukhani, Jayesh J., Pawar, Prafulla, Mittal, Ravindra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014645/ https://www.ncbi.nlm.nih.gov/pubmed/24818110 http://dx.doi.org/10.4103/2278-330X.130466 |
Ejemplares similares
-
Pediatric oncology services in Nepal
por: Sah, Kailash Prasad, et al.
Publicado: (2014) -
Barriers for early detection of cancer amongst Indian rural women
por: Tripathi, Neha, et al.
Publicado: (2014) -
The preventative effect of ramosetron on postoperative nausea and vomiting after total thyroidectomy
por: Lee, Dong Chul, et al.
Publicado: (2011) -
Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
por: Kim, Won Oak, et al.
Publicado: (2011) -
A retrospective study of clinico-pathological spectrum of carcinoma breast in a West Delhi, India
por: Nigam, Jitendra Singh, et al.
Publicado: (2014)